

H15
6-25-01
R2MRD
2-22-01
IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re application of: Gentz, *et al.*

Application Serial No.: 09/006,352

Group Art Unit: 1632

Filed: January 13, 1998

Examiner: Beckerleg, A.

Title: Tumor Necrosis Factor
Receptors 6alpha and 6beta

Attorney Docket No.: PF454

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to References AG-BB listed on the attached revised Form PTO/SB/08. Copies of References AG-BB are enclosed herewith.

Applicants note that reference BI, International Publication WO99/46376, is not in the English Language. In accordance with 37 C.F.R. § 1.98(a)(3), a concise explanation of the relevance of this reference in the English Language is found in the Abstract on the first page of International Publication WO99/46376. Additionally, Applicants wish to draw the Examiner's attention to SEQ ID NOs:1 and 2 of International Publication WO99/46376.


Applicants respectfully request that the Examiner review the materials and information identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is believed due in connection herewith since it is believed this information disclosure statement is being filed before the mailing date of a first Office Action on the merits. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425.

Respectfully submitted

Date: FEBRUARY 22, 2001


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicant
Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

Enclosure